Matthew J. Reilley, MD | Oncology | UVA

Dr. Matthew J. Reilley

Claim this profile

University of Virginia Cancer Center

Studies Cancer
Studies Pancreatic Cancer
16 reported clinical trials
43 drugs studied

Area of expertise

1Cancer
Matthew J. Reilley has run 7 trials for Cancer. Some of their research focus areas include:
Stage IV
KRAS positive
BRAF positive
2Pancreatic Cancer
Matthew J. Reilley has run 7 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
KRAS positive
BRAF positive

Affiliated Hospitals

Image of trial facility.
University Of Virginia Cancer Center
Image of trial facility.
University Of Virginia

Clinical Trials Matthew J. Reilley is currently running

Image of trial facility.

NDI-219216

for Cancer

The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? What kind of effects does NDI-219216 have on the body? Does NDI-219216 have any impact on tumor size? Participants will: Take NDI-219216 every day by mouth. Visit the clinic 6 times during Cycle 1, 2 times during Cycle 2, once a month thereafter for checkups and tests while on the study, then one time for an end of treatment visit. After the End of Study, a follow up will occur but can be done on the phone. Keep a diary of their tablet consumption and symptoms experienced.
Recruiting1 award Phase 1 & 22 criteria
Image of trial facility.

Ipatasertib + Chemotherapy

for Cancer

This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.
Recruiting1 award Phase 2

More about Matthew J. Reilley

Clinical Trial Related1 year of experience running clinical trials · Led 16 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Matthew J. Reilley has experience with
  • Oxaliplatin
  • Fluorouracil
  • Binimetinib
  • Palbociclib
  • Pembrolizumab
  • Leucovorin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Matthew J. Reilley specialize in?
Is Matthew J. Reilley currently recruiting for clinical trials?
Are there any treatments that Matthew J. Reilley has studied deeply?
What is the best way to schedule an appointment with Matthew J. Reilley?
What is the office address of Matthew J. Reilley?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security